Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Phase 2

Terminated

Brief Summary: This study proposes to evaluate the therapeutic efficacy, immunologic effects and normalization of laboratory parameters for patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) when administered one unit (approximately 200 mL) of convalescent plasma administered over a period of one hour. Following administration of the convalescent plasma, physical exam/clinical assessment information is collected daily and routine lab result data is collected every three days.

Detailed Description: Following the administration of one unit (approximately 200 mL) of convalescent plasma over one hour, the study proposes to determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) by prevention of progression to severe or life threatening COVID-19 during the current hospitalization as determined by evaluating if the patient experienced the following the following: respiratory rate \>30/min, Blood oxygen saturation \<93%, partial pressure of arterial oxygen to fraction of inspired oxygen ration \<300, or received a medical diagnosis of respiratory failure, septic shock or multiple organ dysfunction/failure. This will be captured from the daily physical exam/clinical assessment done as part of routine care and at discharge.

The study also proposes to determine the immunologic effects of convalescent plasma infusion as measured by serial SARS-CoV-2 Ag levels through RT-PCR measured by CoV PCR collected at enrollment, day 7 and discharge.

Finally, the study intends to measure normalization of laboratory parameters for risk which will be documented every 3 days while the patient is hospitalized until the time that lab value returns to within the institution's normal range.

Recruitment & Eligibility

Inclusion Criteria

With any of the following:

AND one of the following:

viii. Age over 60 years
ix. Underlying Active Malignancy
x. Cardiovascular Disease
xi. Active Tobacco Use
xii. History of Pulmonary Volume Reduction Surgery
xiii. Hypertension
Prior Treatment: Patients are still eligible for this trial if active antimicrobial agents are in use. Patients are also eligible if they had been treated on COVID-19 clinical trial in the course of their disease.
Age ≥ 18 years.
The effects of allogeneic plasma infusion on the developing fetus is unknown. For this reason women who are pregnant are not eligible to participate.
Agrees to required laboratory data collected which will include the baseline organ function and regular ongoing assessments done as part of routine care.
Ability to understand and the willingness to sign a written informed consent document or ability to have consent provided by Legally Authorized Representative.

Exclusion Criteria

4.2.1 Patients who do not meet above inclusion criteria are not eligible.
4.2.2 Patients may not be receiving any other investigational agents.
4.2.3 History of allergic reactions attributed to previous transfusion history.
4.2.4 Respiratory rate >30/min
4.2.5 Blood oxygen saturation <93%
4.2.6 Partial pressure of arterial oxygen to fraction of inspired oxygen ration <300
4.2.7 Diagnosis of respiratory failure, septic shock or multiple organ dysfunction/failure

Arm && Interventions

Group	Intervention	Description
Treatment Arm	Convalescent Plasma	Study is single arm all patients hospitalized meeting inclusion/exclusion criteria and providing informed consent to receive one unit (approximately 200 mL) of convalescent plasma with data collected daily on routine (non-research) clinical assessments/physical exams and lab results.

Primary Outcome Measures

Name	Time	Method
Determine the Therapeutic Efficacy (Response Rate) of Convalescent Plasma Infusion in Patients at High Risk for Mortality When Infected by SARS-CoV-2 (COVID-19).	Through study completion, an average of 30 days	Measured by respiratory rate \>30/min, blood oxygen saturation \<93%, partial pressure of arterial oxygen to fraction of inspired oxygen ration \<300 and received a medical diagnosis of respiratory failure, septic shock or multiple

Secondary Outcome Measures

Name	Time	Method
Determine the Immunologic Effects of Convalescent Plasma Infusion	Through study completion, an average of 14 days	SARS-CoV-2 Ag levels through RT-PCR
Absolute Lymphocyte Count (10*3/uL)	Through study completion, an average of 14 days	Measure normalization of laboratory parameters for risk
Reatinine Kinase (mg/dL)	Through study completion, an average of 14 days	Measure normalization of laboratory parameters for risk
C-reactive Protein (mg/dl)	Through study completion, an average of 14 days	Measure normalization of laboratory parameters for risk
D-Dimer (ng/ml FEU)	Through study completion, an average of 14 days	Measure normalization of laboratory parameters for risk
Interleukin-6 (pg/ml)	Through study completion, an average of 14 days	Measure normalization of laboratory parameters for risk
Ferritin (ng/mL)	Through study completion, an average of 14 days	Measure normalization of laboratory parameters for risk

Locations (4): Norton Brownsboro Hospital
🇺🇸
Louisville, Kentucky, United States
Norton Hospital
🇺🇸
Louisville, Kentucky, United States
Norton Women's and Children's Hospital
🇺🇸
Louisville, Kentucky, United States
Norton Audubon Hospital
🇺🇸
Louisville, Kentucky, United States